Linked Life Data

19431209

Source:http://linkedlifedata.com/resource/pubmed/id/19431209

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19431209rdf:typepubmed:Citationlld:pubmed
pubmed-article:19431209lifeskim:mentionsumls-concept:C0346647lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C0302600lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C1522496lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C1334126lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:19431209lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:19431209pubmed:issue5lld:pubmed
pubmed-article:19431209pubmed:dateCreated2009-7-21lld:pubmed
pubmed-article:19431209pubmed:abstractTextAngiogenesis is essential for tumor growth and metastasis. Although ELR(+)-CXC-chemokines and their corresponding receptor, CXC-receptor 2 (CXCR2), are known mediators of angiogenesis, little is known about their role in pancreatic cancer (PaCa). The aim of our study was to determine the role of ELR(+)-CXC-chemokine/CXCR2 biological axis in promoting PaCa angiogenesis. We prospectively collected secretin-stimulated exocrine pancreatic secretions (SSEPS) from normal individuals (NP) and PaCa patients. We showed that summed concentrations of ELR(+)-CXC-chemokines in SSEPS from PaCa patients were significantly higher than in those from NP (p = 0.002). We measured ELR(+)-CXC-chemokine levels in supernatants from multiple PaCa cell lines and confirmed that BxPC-3, Colo-357 and Panc-28 had significantly higher expression compared with an immortalized human pancreatic ductal epithelial (HPDE) cell line. After confirming lack of autocrine effects of ELR(+)-CXC-chemokines on PaCa cells (due to absence of CXCR2 expression), we investigated paracrine effects of these chemokines on human umbilical vein endothelial cells (HUVEC). Both recombinant ELR(+)-CXC-chemokines and co-culturing with BxPC-3 significantly enhanced proliferation, invasion, and tube formation of HUVEC (p < 0.05). These biological effects were significantly inhibited by treatment with a neutralizing antibody against CXCR2 (anti-CXCR2 Ab) (p < 0.05). Finally, anti-CXCR2 Ab significantly reduced tumor volume (p < 0.05), Ki-67 proliferation index (p = 0.043) and Factor VIII(+) microvessel density (p = 0.004) in an orthotopic nude mouse PaCa model. Our results show that ELR(+)-CXC-chemokines promote PaCa tumor-associated angiogenesis through CXCR2, suggesting that CXCR2 is an anti-angiogenic target in PaCa.lld:pubmed
pubmed-article:19431209pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:languageenglld:pubmed
pubmed-article:19431209pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:citationSubsetIMlld:pubmed
pubmed-article:19431209pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19431209pubmed:statusMEDLINElld:pubmed
pubmed-article:19431209pubmed:monthSeplld:pubmed
pubmed-article:19431209pubmed:issn1097-0215lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:WoodwardTimot...lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:GuhaSushovanSlld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:StrieterRober...lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:HoffmanRobert...lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:BurdickMarie...lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:WallaceMichae...lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:TongZhiminZlld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:RaimondoMassi...lld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:YangZhijianZlld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:MatsuoYoichiYlld:pubmed
pubmed-article:19431209pubmed:authorpubmed-author:GillKanwar...lld:pubmed
pubmed-article:19431209pubmed:copyrightInfo2009 UICC.lld:pubmed
pubmed-article:19431209pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19431209pubmed:day1lld:pubmed
pubmed-article:19431209pubmed:volume125lld:pubmed
pubmed-article:19431209pubmed:ownerNLMlld:pubmed
pubmed-article:19431209pubmed:authorsCompleteYlld:pubmed
pubmed-article:19431209pubmed:pagination1027-37lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:meshHeadingpubmed-meshheading:19431209...lld:pubmed
pubmed-article:19431209pubmed:year2009lld:pubmed
pubmed-article:19431209pubmed:articleTitleCXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer.lld:pubmed
pubmed-article:19431209pubmed:affiliationDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.lld:pubmed
pubmed-article:19431209pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19431209pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:19431209pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:19431209pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19431209lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19431209lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19431209lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19431209lld:pubmed